Schizophrenia
-
Scientists investigating the driving factors behind certain neurological diseases have uncovered a new class of proteins that could help us intervene in some of the destructive processes that take place in the brain.
-
A new study investigating brain activity patterns in schizophrenia patients and their siblings is suggesting a specific brain “signature” could detect the condition in subjects before clinical symptoms appear.
-
A study has homed in on the sex-specific activity of a gene that both increases risk of developing schizophrenia and decreases the risk of developing lupus, offering novel insights into how some diseases appear in different rates in men and women.
-
Promising new research from the University of California, Los Angeles (UCLA), suggests an old schizophrenia drug could significantly enhance the efficacy of radiation treatment for one of the deadliest forms of brain cancer.
-
A new study is reporting the successful results of a clinical trial testing an experimental drug designed to treat psychosis in schizophrenia. The drug works unlike any other existing anti-psychotic medication and larger Phase 3 trials are underway.
-
New research has analyzed hundreds of brain scans from patients with schizophrenia revealing two distinct subtypes with differences in gray matter volumes, busting the previously held notion that all schizophrenia patients' brains are the same.
-
A team of researchers from King’s College London has, for the first time, imaged the brains of patients with psychosis under the influence of CBD. The study demonstrates the anti-psychotic potential of CBD, suggesting clinical trials are necessary.
-
A team of UK researchers has, for the first time in living human brains, demonstrated how the cognitive dysfunction seen in schizophrenia may be caused by the lack of a key protein known to facilitate communication between neurons in the brain.
-
Sparking new dogs versus cats arguments, a study is suggesting exposure to a pet dog over a child’s first years can be linked to a lower risk of developing schizophrenia as an adult. The same correlation was not seen in children raised with cats.
-
A new drug designed to treat acute psychosis in schizophrenic patients is reporting positive results from a Phase 2 clinical trial. After several decades of development the drug is hoped to reach the market in the next few years.
-
A new study from a team of Japanese researchers is presenting a novel hypothesis as to the cause of a subtype of schizophrenia. The study also suggests a biomarker in human follicles could allow future diagnoses to be made using a single hair.
-
A new study has for the first time revealed one of the molecular mechanisms by which CBD directly blocks the negative psychiatric side effects generated by THC.
Load More